In a clinically relevant NUP98::NSD1 PDX model, we found that MLL–Menin inhibition can completely eradicate this aggressive AML subtype even when a concurrent FLT3-ITD mutation was present. The gene discussed is NUP98; the disease is acute myeloid leukemia.